Source comparison
Best Tesamorelin + Ipamorelin Blend Dosage for Visceral Fat: Research Protocol Comparison
This table compares the most common research dosing protocols based on published studies and investigator-reported outcomes. | Protocol | Tesamorelin Dose | Ipamorelin Dose | Dosing Frequency | Reported VAT Reduction (26 weeks) | Notable Findings | Professiona
This comparison does not assign a generated winner or score.
- This table compares the most common research dosing protocols based on published studies and investigator-reported outcomes.
- | Protocol | Tesamorelin Dose | Ipamorelin Dose | Dosing Frequency | Reported VAT Reduction (26 weeks) | Notable Findings | Professional Assessment ||—|—|—|—|—|—|| Standard Clinical (FDA-approved monotherapy) | 2mg daily | None | Once daily (morning) | 12–15% | Well-tolerated, established safety profile, visceral-selective | Baseline standard. Proven efficacy but monotherapy limits GH pulse frequency || Low-Dose Blend | 1mg daily | 200mcg | Tes 1×/day, Ipa 2×/day | 10–14% | Lower side effect incidence, reduced cost, slower onset | Best for initial trials or those sensitive to GH effects. Efficacy present but attenuated || Moderate Blend (most research protocols) | 1–2mg daily | 250–300mcg | Tes 1×/day, Ipa 2–3×/day | 15–22% | Sequential dosing shows superior outcomes vs simultaneous, ipamorelin timing around activity windows enhances oxidation | Optimal balance. Maximises visceral selectivity while maintaining tolerability and cost-effectiveness || High-Frequency Blend | 2mg daily | 30